id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0319-0004,FDA,FDA-2003-N-0319,"Agency Information Collection, Activities; Submission for Office of Management and Budget Review; Comment Request; Study to Measure the Compliance of Prescribers With the Contraindication of the Use of Triptans in Migraine Headache Patients With Vascular Disease",Notice,30 Day Proposed Information Collection,2005-11-10T05:00:00Z,2005,11,2005-11-02T05:00:00Z,2005-12-03T04:59:59Z,2025-06-17T17:03:30Z,05-21807,0,0,09000064804956b9
FDA-2003-N-0319-0002,FDA,FDA-2003-N-0319,Draft Questions to be Used with the RSR Project,Supporting & Related Material,Background Material,2003-12-01T05:00:00Z,2003,12,,,2025-06-17T17:11:00Z,,0,0,0900006480495694
FDA-2003-N-0319-0003,FDA,FDA-2003-N-0319,Draft Questions to be Used with the RSR Project,Supporting & Related Material,Background Material,2003-12-01T05:00:00Z,2003,12,,,2025-06-17T17:18:17Z,,0,0,09000064804956a5
FDA-2003-N-0319-0001,FDA,FDA-2003-N-0319,Agency Information Collection Activities; Proposed Collection; Comment Request; Study to Measure the Compliance of Prescribers With the Contraindication of the Use of Triptans in Migraine Headache Patients With Vascular Disease,Notice,60 Day Proposed Information Collection,2003-11-17T05:00:00Z,2003,11,2003-11-17T05:00:00Z,2004-01-17T04:59:59Z,2025-06-25T15:30:11Z,,0,0,0900006480495652